Argenx Shares 'Round Tripping,' Driven by Drug Development Updates, RBC Says

MT Newswires Live10-20

Argenx (ARGX) shares have been "round tripping," with the volatility driven by the company's recent drug development updates, RBC Capital Markets said in a Tuesday note.

Highs in early August were driven by positive results from the company's phase 3 study of Vyvgart Hytrulo in adults with autoimmune myositis, but were offset by Argenx's discontinuation of its phase 3 trial of the product candidate in adults with moderate-to-severe Sjogren's disease, the brokerage said.

Shares were also weighed down by a "tough degrossing biotech tape," pulling prices back to low $800s, RBC noted.

According to RBC, investors could be undervaluing the company's breakthrough in celiac disease, with a competitive product candidate that remains to be added to their Argenx models.

RBC has an outperform rating on Argenx, with a lower price target of $1,025 from $1,100.

Price: 878.14, Change: +52.53, Percent Change: +6.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment